NASDAQ:BCEL Atreca (BCEL) Stock Price, News & Analysis $0.09 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.0952-Week Range$0.05▼$1.20VolumeN/AAverage Volume4.61 million shsMarket Capitalization$3.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Atreca alerts: Email Address Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Atreca Stock (NASDAQ:BCEL)Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Read More BCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCEL Stock News HeadlinesAugust 20, 2024 | seekingalpha.comBicycle Therapeutics Is Looking Increasingly AttractiveApril 23, 2024 | ca.finance.yahoo.comAtreca, Inc. (BCEL) Stock Price, News, Quote & History - Yahoo FinanceSeptember 8, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…April 21, 2024 | nz.finance.yahoo.comAtreca, Inc. (0C1.MU)February 18, 2024 | wsj.comAtreca Inc. Cl AFebruary 15, 2024 | benzinga.comAtreca Stock (NASDAQ:BCEL), Short Interest ReportFebruary 7, 2024 | msn.comAtreca Inc Announces Executive Departures and Consulting AgreementsDecember 29, 2023 | bizjournals.comImmunome to buy assets from California biotech companySeptember 8, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…December 26, 2023 | tmcnet.comBCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.December 21, 2023 | thestreet.comAtreca Inc.December 11, 2023 | benzinga.comAtreca Stock (NASDAQ:BCEL) Dividends: History, Yield and DatesNovember 16, 2023 | morningstar.comAtreca Inc Class A BCELNovember 14, 2023 | marketwatch.comAtreca to Cut About 40% of WorkforceNovember 14, 2023 | finance.yahoo.comAtreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic AlternativesNovember 2, 2023 | es.investing.comAtreca Inc (BCEL)October 24, 2023 | finance.yahoo.comBAKER BROS. ADVISORS LP Reduces Stake in Atreca IncOctober 12, 2023 | benzinga.comWhat's Going On With Atreca Inc Stock?See More Headlines Receive BCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today9/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCEL CUSIPN/A CIK1532346 Webwww.atreca.com Phone(650) 595-2595FaxN/AEmployees130Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-157.90% Return on Assets-71.39% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.04Miscellaneous Outstanding Shares39,624,000Free Float35,146,000Market Cap$3.57 million OptionableOptionable Beta1.03 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. John A. Orwin M.B.A. (Age 59)President, CEO, Director & Principal Financial Officer Comp: $927.03kDr. Tito A. Serafini Ph.D. (Age 61)Founder & Director Comp: $665.5kMr. Rick Ruiz (Age 60)Principal Accounting Officer Ms. Courtney J. Phillips J.D. (Age 49)General Counsel & Corporate Secretary Roger Richard RuizVice President of FinanceKey CompetitorsTrinity BiotechNASDAQ:TRIBIndaptus TherapeuticsNASDAQ:INDPFlora GrowthNASDAQ:FLGCLongeveronNASDAQ:LGVNOncternal TherapeuticsNASDAQ:ONCTView All CompetitorsInsidersBros. Advisors Lp BakerSold 274,739 sharesTotal: $109,895.60 ($0.40/share)View All Insider Transactions BCEL Stock Analysis - Frequently Asked Questions How have BCEL shares performed this year? Atreca's stock was trading at $0.1320 at the beginning of the year. Since then, BCEL stock has decreased by 31.8% and is now trading at $0.09. View the best growth stocks for 2024 here. How were Atreca's earnings last quarter? Atreca, Inc. (NASDAQ:BCEL) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.74). What is John Orwin's approval rating as Atreca's CEO? 6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend. When did Atreca IPO? Atreca (BCEL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers. How do I buy shares of Atreca? Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Atreca own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO) and Hookipa Pharma (HOOK). This page (NASDAQ:BCEL) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atreca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atreca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
